870640-64-5 Usage
Description
(3R,4S,5S)-tert-butyl 4-(benzyl(methyl)amino)-3-methoxy-5-methylheptanoate is a complex organic compound with a molecular formula of C18H31NO3. It is a tertiary butyl ester derivative of a 5-substituted heptanoic acid, featuring a benzyl(methyl)amino moiety attached to the 4th carbon and a methoxy and methyl group attached to the 3rd and 5th carbon, respectively. This synthetic compound possesses a unique structure and functional groups, which may endow it with potential applications in the pharmaceutical and chemical industries, as well as possible biological activity or interactions with other molecules.
Uses
Used in Pharmaceutical Industry:
(3R,4S,5S)-tert-butyl 4-(benzyl(methyl)amino)-3-methoxy-5-methylheptanoate is used as a potential pharmaceutical candidate for the development of new drugs due to its unique structure and functional groups. Its complex nature may allow it to interact with biological targets or be modified for specific therapeutic applications.
Used in Chemical Industry:
In the chemical industry, (3R,4S,5S)-tert-butyl 4-(benzyl(methyl)amino)-3-methoxy-5-methylheptanoate may serve as an intermediate in the synthesis of other complex organic compounds or as a component in the formulation of specialty chemicals. Its versatility in structure lends itself to various chemical reactions and potential uses in different chemical processes.
Check Digit Verification of cas no
The CAS Registry Mumber 870640-64-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,0,6,4 and 0 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 870640-64:
(8*8)+(7*7)+(6*0)+(5*6)+(4*4)+(3*0)+(2*6)+(1*4)=175
175 % 10 = 5
So 870640-64-5 is a valid CAS Registry Number.
870640-64-5Relevant articles and documents
COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER
-
Page/Page column 113, (2017/05/17)
The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention reates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER
-
, (2016/11/17)
The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody consisting of the Trastuzumab, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS
-
, (2014/11/13)
The present invention concerns a compound of following formula (I) where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is: - an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or - a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
